Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02282930 · ClinicalTrials.gov registry record · Phase 3
Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
A Phase 3 study of Proteinuria and Progressive IgA Nephropathy, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Enrollment target
- 4
- Study locations
NCT02282930 is a Phase 3 study of Proteinuria and Progressive IgA Nephropathy that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 204-participant average among 10 other Proteinuria trials with a reported enrollment target (90% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02282930, a Phase 3 study of Proteinuria and Progressive IgA Nephropathy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
Conditions Studied
Interventions
- DRUG ACTH (Acthar) Gel
Study Locations (4)
California
- Stanford University - Palo Alto
Florida
- Mayo Clinic Jacksonville - Jacksonville
Minnesota
- Mayo Clinic in Rochester - Rochester
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-03 |
| Est. Completion | 2018-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02282930
The ClinicalTrials.gov registry entry for NCT02282930 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 204-participant average among 10 other Proteinuria trials with a reported enrollment target (90% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Proteinuria appearing as the primary indexed condition, and to 1 intervention - of which ACTH (Acthar) Gel is the first listed.
NCT02282930 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02282930 about?
NCT02282930 is a clinical study titled "Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression". This study is designed to answer whether patients with progressive IgA nephropathy, who receive Acthar (ACTH) gel injection at a dose of 80 units subcutaneously twice weekly for 6 months is effective in inducing improvement in proteinuria and renal function.
What is the current status of trial NCT02282930?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 20 participants. The study started on 2015-03. Estimated completion is 2018-06-30.
What conditions does trial NCT02282930 study?
This clinical trial studies the following conditions: Proteinuria, Progressive IgA Nephropathy.
What interventions are being tested in trial NCT02282930?
The interventions under investigation include: ACTH (Acthar) Gel (DRUG).
Who is sponsoring clinical trial NCT02282930?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02282930 being conducted?
This trial has 4 study locations across California, Florida, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proteinuria
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
RECRUITING · Phase 3
-
The Effects of Vitamin D Repletion in Vitamin D Deficient Patients With Stage 3 and 4 Chronic Kidney Disease
COMPLETED · Phase 3
-
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
RECRUITING · Phase 2
-
Proteinuria in Pre and Post Transplant
RECRUITING
-
Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.